Trials / Completed
CompletedNCT04247074
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 413 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin neuromodulator | QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL |
| BIOLOGICAL | Placebo | Placebo will be injected into either the LCL, GL, or both the LCL and GL |
Timeline
- Start date
- 2020-02-10
- Primary completion
- 2020-10-02
- Completion
- 2021-02-26
- First posted
- 2020-01-29
- Last updated
- 2023-09-06
- Results posted
- 2023-09-06
Locations
12 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04247074. Inclusion in this directory is not an endorsement.